Literature DB >> 12005265

The time course study of osteoinduction by bone morphogenetic protein-2 via adenoviral vector.

Y Okubo1, K Bessho, K Fujimura, S Kaihara, T Iizuka, S Miyatake.   

Abstract

We evaluated the time course of osteoinduction by an adenoviral vector, AxCAOBMP-2, in normal rats (Group I) and 2 immunosuppressed groups (Groups II and III). Immunosuppression was induced by 125 mg/kg of cyclophosphamide injected intraperitoneally the day before vector injection. Groups I and III received a high dose of AxCAOBMP-2 (25 microl; 8.75 x 10(8) pfu) and Group II a low dose (5 microl; 1.75 x 10(8) pfu). Each dose of AxCAOBMP-2 was injected into the right calf muscle of rats. On days 7, 14 and 21 postinjection, the osteoinducive activity in each group was investigated radiologically, histologically, immunohistochemically and biochemically. Osteoinduction was observed only in Groups II and III on days 14 and 21. The activity of osteoinduction in Group III was higher than that in Group II. There was little difference in the expression of LacZ between Groups I and III on day 3. However, there was a marked difference in BMP-2 protein expression between Groups I and III on day 7 postinjection. We speculated that the reason for this was that most of the infected cells were eliminated by the immune system of the host from days 3 to 7. These results suggest that gene therapy with AxCAOBMP-2 under transient immunosuppression may be useful for bone reconstruction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12005265     DOI: 10.1016/s0024-3205(01)01393-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  BMP gene delivery for alveolar bone engineering at dental implant defects.

Authors:  Courtney A Dunn; Qiming Jin; Mario Taba; Renny T Franceschi; R Bruce Rutherford; William V Giannobile
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

2.  Comparison of osteogenic potentials of human rat BMP4 and BMP6 gene therapy using [E1-] and [E1-,E2b-] adenoviral vectors.

Authors:  Hongwei Li; Jin Zhong Li; Debra D Pittman; Andy Amalfitano; Gerald R Hankins; Gregory A Helm
Journal:  Int J Med Sci       Date:  2006-06-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.